Podcast

Leukemia Experts Reflect on Defining Moments as Women in the Field

Author(s):

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we passed the mic to Catherine E. Lai, MD, MPH, an associate professor and physician leader of the Leukemia Clinical Research Unit at the University of Pennsylvania Perelman Center for Advanced Medicine, who moderated a discussion for OncLive’s Women in Oncology series.

Dr Lai was joined by Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD.

Luger is an attending physician, professor of medicine, and interim director of the Penn-Vinmec Oncology Center of Excellence at the Hospital of the University of Pennsylvania. Roboz is a professor of medicine and the director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the NewYork-Presbyterian Hospital. Stock is the Anjuli Seth Nayak Professor of Medicine and a professor in the Comprehensive Cancer Research Center at the University of Chicago Medicine.

In our exclusive interview, Drs Luger, Roboz, and Stock discussed the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also shared their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.